Securing Earnings and Focusing Management Resources
First written in FY2016. 16 of 26 entries say "Advanced", first in FY2018. Latest entry: 2026-08-07.
Immuno-Biological Laboratories moved to the "Worse" side of this theme in 2019, 4 years before the typical company in this theme (2023).
67 other companies' latest entry also says "Advanced".
- 2026-08-07AdvancedEarnings
「As a result, the Group’s consolidated net sales increased 35.2% year on year to ¥286.008 million, while operating income rose 116.5% to ¥117.773 million.」
Consolidated net sales and operating income exceeded the previous year’s first-quarter results, indicating progress in securing earnings. - FY2026AdvancedAnnual report
「During the consolidated fiscal year, operating results improved due to strong operating activities and the effects of expense reductions. Cash provided by operating activities was ¥301.093 million.」
Cash provided by operating activities increased from ¥183.495 million in the previous year to ¥301.093 million due to strong operating activities and the effects of expense reductions. - FY2026-H1AdvancedAnnual report
「Operating profit increased 109.0% year on year to ¥142.124 million due to higher revenue, lower costs following the closure of the Akita Analysis Center in Akita Prefecture and consolidation of its operations at the IBL Analysis Center in Gunma Prefecture, improved productivity and further cost controls.」
The closure and consolidation of the Akita Analysis Center, cost reductions, improved productivity and cost controls increased consolidated operating profit 109.0% year on year to ¥142.124 million. - FY2025AdvancedAnnual report
「During the consolidated fiscal year, operating results improved due to strong operating activities and the selective and focused allocation of research themes in the genetically modified silkworm services business. Cash provided by operating activities was ¥183.495 million.」
Cash provided by operating activities increased from ¥133.775 million in the previous year to ¥183.495 million through the selective and focused allocation of research themes and more efficient business operations. - FY2025-H1AdvancedAnnual report
「As a result, consolidated revenue increased 21.5% from the previous year to ¥444.127 million, while consolidated operating profit increased 411.3% from the previous year to ¥68.002 million, due to higher revenue and efforts to control costs.」
Higher revenue and cost controls improved consolidated operating profit from ¥13.300 million in the same period of the previous year to ¥68.002 million, indicating quantitative progress toward securing earnings. - FY2024AdvancedAnnual report
「During the consolidated fiscal year, operating results improved due to strong operating activities and a selective, focused approach to research themes in the genetically modified silkworm services business. Cash provided by operating activities was ¥133.775 million.」
Operating results improved through the selective and focused allocation of research themes, resulting in ¥133.775 million in cash provided by operating activities. - FY2024-Q1RestatedAnnual report
「Because the timing for achieving the target could not be determined and the Group decided to concentrate its limited funds on developing raw materials for in-vitro diagnostic products and other products in the antibody-related business, it discontinued new development aimed at producing pharmaceutical raw materials using genetically modified silkworms.」
The Group has reaffirmed its policy of concentrating limited funds on raw materials for in-vitro diagnostic products and other products in the antibody-related business. - FY2023AdvancedAnnual report
「SG&A expenses declined 6.1% year on year to ¥468.338 million, partly because research themes in the genetically modified silkworm development business shifted toward basic research.」
A shift in research themes toward basic research and the optimization of business activities reduced SG&A expenses, improving consolidated operating results from an operating loss of ¥122.219 million in the previous year to operating profit of ¥58.373 million. - FY2023-Q3AdvancedAnnual report
「In terms of expenses, the Group optimized its business activities amid the COVID-19 pandemic and reduced R&D expenses for genetically modified silkworms as well as SG&A expenses through a selective and focused approach to R&D.」
The optimization of business activities and the selective, focused approach to R&D reduced R&D expenses for genetically modified silkworms and SG&A expenses, contributing to a return to operating profitability. - FY2023-Q2AdvancedAnnual report
「In terms of expenses, the Group optimized its business activities amid the COVID-19 pandemic and reduced SG&A expenses through a selective and focused approach to R&D. As a result, revenue was ¥293.166 million, up 15.4% year on year, and the operating loss improved substantially to ¥54.561 million, compared with an operating loss of ¥136.520 million in the same period of the previous year.」
SG&A expenses declined due to the optimization of business activities and a selective and focused approach to R&D, narrowing the operating loss from ¥136.520 million in the same period of the previous year to ¥54.561 million. - FY2023-Q1AdvancedAnnual report
「In terms of expenses, the Group optimized its business activities amid the COVID-19 pandemic and reduced SG&A expenses through a selective and focused approach to R&D. As a result, revenue was ¥156.456 million, up 25.0% year on year, and the operating loss was ¥14.858 million, compared with an operating loss of ¥73.893 million in the same period of the previous year.」
SG&A expenses declined due to the optimization of business activities and a selective and focused approach to R&D. Revenue increased 25.0% year on year, while the operating loss narrowed from ¥73.893 million to ¥14.858 million. - FY2022-Q3AdvancedAnnual report
「During the first 3 quarters of the consolidated fiscal year, the Group's revenue showed signs of recovery, centered on sales of its core reagent-related ELISA kits and antibodies, as R&D activities at companies and universities in Japan and overseas began to recover. Although the absorption-type merger of SkyLight Biotech Co., Ltd. (a wholly owned subsidiary), conducted as a simplified and abbreviated merger, temporarily increased expenses, SG&A expenses declined due to restraints on domestic and overseas travel expenses to prevent the spread of COVID-19 and a selective, focused approach to R&D. As a result, revenue was ¥448.082 million, up 8.1% year on year, and the operating loss was ¥136.678 million, compared with an operating loss of ¥230.684 million in the same period of the previous year.」
SG&A expenses declined due to a selective and focused approach to R&D and restraints on travel expenses, narrowing the operating loss from ¥230.684 million in the same period of the previous year to ¥136.678 million. - FY2022-Q1AdvancedAnnual report
「In terms of profit, SG&A expenses declined as the Company continued to limit domestic and overseas travel expenses to prevent the spread of COVID-19 and applied a selective and focused approach to R&D. As a result, revenue was ¥125.150 million, up 7.3% year on year, and the operating loss was ¥73.893 million, compared with an operating loss of ¥101.611 million in the same period of the previous year.」
SG&A expenses declined due to restraints on domestic and overseas travel expenses and a selective, focused approach to R&D, narrowing the operating loss from ¥101.611 million in the same period of the previous year to ¥73.893 million. - FY2021MitigatedAnnual report
「During the consolidated fiscal year, revenue increased slightly from the previous fiscal year. SG&A expenses were not significant because R&D expenses related to anti-HIV antibodies and other projects in the genetically modified silkworm business declined and there were no major purchases of fixed assets.」
The decline in R&D expenses and the absence of large-scale fixed-asset purchases reduced the SG&A burden, lowering the costs associated with securing earnings and concentrating resources from the previous fiscal year. - FY2021-Q1Higher SG&A expenses due to increased R&D expensesAnnual report
「SG&A expenses increased as R&D expenses rose with progress in the development of anti-HIV antibody biopharmaceuticals in the genetically modified silkworm business. As a result, the operating loss was ¥101.611 million, compared with an operating loss of ¥104.480 million in the same period of the previous year.」
Although expenses in the sales division declined, SG&A expenses increased due to higher R&D expenses associated with progress in anti-HIV antibody development. The operating loss narrowed slightly, but the Company continued to prioritize R&D investment and remained in the red. - FY2020WorsenedAnnual report
「The Group has prioritized the allocation of R&D expenses because joint research in the genetically modified silkworm business is progressing smoothly. SG&A expenses also increased substantially due to the significant costs incurred for construction of the management product storage building, among other factors.」
While continuing to reduce expenses, SG&A expenses increased due to the prioritized allocation of R&D expenses and costs for construction of the management product storage building, among other items, widening the operating loss to ¥595.359 million. - FY2020-Q3WorsenedAnnual report
「SG&A expenses increased as R&D expenses rose in the genetically modified silkworm business due to renovation work at the Mikasa Research Institute and progress in research on biopharmaceuticals, including anti-HIV antibodies. As a result, the operating loss was ¥298.801 million, compared with an operating loss of ¥65.718 million in the same period of the previous year.」
R&D expenses increased due to renovation work at the Mikasa Research Institute and progress in research on anti-HIV antibodies and other projects, widening the operating loss from ¥65.718 million in the same period of the previous year to ¥298.801 million. - FY2020-Q2WorsenedAnnual report
「SG&A expenses increased as R&D expenses rose with progress in research on biopharmaceuticals, including anti-HIV antibodies, in the genetically modified silkworm business. As a result, the operating loss was ¥209.844 million, compared with an operating loss of ¥37.512 million in the same period of the previous year.」
R&D expenses increased as research on anti-HIV antibodies and other projects progressed, widening the operating loss from ¥37.512 million in the same period of the previous year to ¥209.844 million. - FY2019WorsenedAnnual report
「Although the Group continues to work on reducing costs, it has prioritized the allocation of R&D expenses because joint research in the genetically modified silkworm business is progressing smoothly, and has also increased staffing accordingly.」
While continuing to reduce expenses, the Group's SG&A expenses increased due to the allocation of R&D expenses and personnel to the genetically modified silkworm business and costs for core systems. The operating loss was ¥173.680 million. - FY2018AdvancedAnnual report
「During the consolidated fiscal year, the Group worked toward turning operating cash flow positive as its primary objective, while reducing expenses and restraining capital investment.」
The Group reduced expenses and restrained capital investment, resulting in ¥73.847 million in cash provided by operating activities. The efforts to secure earnings and concentrate management resources were accompanied by tangible progress in achieving positive operating cash flow. - FY2017RestatedAnnual report
「The Group will continue reviewing existing products and reducing costs in indirect functions to secure earnings. It also recognizes the importance of selecting research themes, concentrating management resources and managing operations efficiently.」
The Group continues to pursue product reviews, reductions in indirect-function costs, the selection of research themes and the concentration of management resources. - FY2016First statedAnnual report
「The Group will continue reviewing existing products and reducing costs in indirect functions to secure earnings. It also recognizes the importance of selecting research themes, concentrating management resources and managing operations efficiently.」
Product reviews, reductions in indirect-function costs and the selection of research themes are being used to concentrate resources and secure earnings.